Can a maintenance chemo drug extend control of advanced sarcoma?

NCT ID NCT06981637

First seen Jan 24, 2026 · Last updated May 16, 2026 · Updated 17 times

Summary

This study is for people with advanced soft tissue sarcoma whose disease is under control after standard chemotherapy. It compares ongoing treatment with a drug called pegylated liposomal doxorubicin (PLD) against simply watching and waiting. The goal is to see if maintenance PLD can delay cancer growth. About 81 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chang Gung Memorial Hospital

    NOT_YET_RECRUITING

    Kaohsiung City, Taiwan

    Contact

  • China Medical University Hospital

    RECRUITING

    Taichung, Taiwan

    Contact

  • Kaohsiung Medical University Chung-Ho Memorial Hospital,

    RECRUITING

    Kaohsiung City, Taiwan

    Contact

  • National Cheng Kung University Hospital

    RECRUITING

    Tainan, Taiwan

    Contact

  • National Taiwan University Hospital

    RECRUITING

    Taipei, Taiwan

    Contact Email: •••••@•••••

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, Taiwan

    Contact

  • Tri-Service General Hospital

    RECRUITING

    Taipei, Taiwan

    Contact

Conditions

Explore the condition pages connected to this study.